IP Library › Granted Patent US 7,465,452
Granted Patent B2
US 7,465,452 · App. 10/062,257 · Granted Dec 16, 2008

Tumor antigen

Assignee: Green Peptide Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,465,452
App. No.
10/062,257
Granted
Dec 16, 2008
Kind
B2
Abstract

The present invention relates to a tumor antigen peptide capable of inducing and/or activating HLA-A24-restricted and/or HLA-A2-restricted and tumor-specific cytotoxic T lymphocytes. The present invention also relates to a method of providing a polynucleotide encoding the peptide and a complementary strand thereto, a recombinant vector containing the polynucleotide, a transformant containing the recombinant vectors. The present invention also relates to a method for producing the peptide, an antibody against the peptide, a compound interacting with these entities and a method for screening for the compound, a pharmaceutical composition utilizing these entities, and a means for the diagnosis utilizing these entities.

Claims (3)

1. A peptide consisting of SEQ ID No:1, 2 or 3.

2. A tumor antigen, wherein the tumor antigen consists of a peptide of claim 1 .

3. A composition comprising at least one peptide selected from a peptide of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Mar 26, 2018
From: GREEN PEPTIDE CO., LTD.
To: BRIGHTPATH BIOTHERAPEUTICS CO., LTD.
Reel/Frame 045725/0058 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2005
From: ITOH, KYOGO
To: GREEN PEPTIDE CO., LTD.
Reel/Frame 016034/0034 →
Priority Claims (1)
JP 11-222101 · Aug 5, 1999 · national
Continuity (2)
Continuation In Part PCTJP000522000 · Aug 3, 2000
Related Publication 20020128201A1 · Sep 12, 2002